Saha A, Hyzy S, Laforest T, et al. CD45-Targeted Antibody-Drug-Conjugate Successfully Conditions for Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2022; (doi: 10.1182/blood.2021012366).
While genotoxic conditioning protocols for hematopoietic stem cell transplantation run the risk of inducing graft-versus-host disease in patients with blood disorders, research suggests CD45-targeted antibody-drug-conjugate (ADC) conditions effectively but with less toxicity. Scientists worked with an anti-mouse CD45-targeted ADC. In several preclinical murine models, preconditioning with CD45-ADC promoted healthy engraftment of donor stem cells and immune reconstitution. As a single agent at a higher dose, the technique produced full donor chimerism — on par with what conditioning via lethal total body irradiation would deliver. Similar results were observed when CD45-ADC was given at a lower dose and in tandem with reduced intensity conditioning.